Related Experiment Video

Updated: Aug 13, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K

Androgen-Independent Prostate Cancer Is Sensitive to CDC42-PAK7 Kinase Inhibition

Hyunho Han1, Cheol Keun Park2,3, Young-Deuk Choi1

  • 1Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.

Biomedicines
|January 21, 2023
PubMed

Insights

Statins can inhibit castration-resistant prostate cancer (CRPC) growth by targeting QKI overexpression, a mechanism previously unknown for this aggressive cancer. This discovery may lead to new treatments for patients resistant to androgen-deprivation therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Androgen-deprivation therapy (ADT) is a primary treatment for prostate cancer.
  • Castration-resistant prostate cancer (CRPC) develops when cancer progresses despite ADT.
  • New therapeutic targets are needed for aggressive CRPC subtypes.

Purpose of the Study:

  • To investigate the therapeutic potential of statins in CRPC.
  • To identify mechanisms by which statins affect CRPC growth.
  • To explore novel treatment strategies for AR-low CRPC.

Main Methods:

  • In silico drug/gene perturbation combined screening.
  • Analysis of RNA-binding protein QKI and microRNA-200 expression.
  • Assessment of statin efficacy in CRPC models.
  • Correlation of PAK7 expression with prostate cancer and hyperlipidemia.

Main Results:

  • Statins selectively inhibit CRPC tumors with QKI overexpression and low androgen receptor (AR).
  • QKI overexpression represses microRNA-200, promoting AR-low mesenchymal-like CRPC cells.
  • QKI-overexpressing cells are vulnerable to CDC42-PAK7 inhibition by statins.
  • PAK7 overexpression is found in prostate cancer with hyperlipidemia.

Conclusions:

  • Statins exhibit a novel mechanism against QKI-expressing, AR-lost CRPC.
  • This finding may explain clinical benefits of statins and supports drug repurposing.
  • Results suggest potential for improved CRPC treatment strategies.
Keywords:
RNA-binding proteinsandrogen deprivation therapycastration-resistant prostate cancerprostate cancerstaints

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.5K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K